financetom
Business
financetom
/
Business
/
Telenor hikes 2024 sales forecast after in-line Q2 earnings
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Telenor hikes 2024 sales forecast after in-line Q2 earnings
Jul 17, 2024 10:49 PM

(Reuters) -Norwegian telecom operator Telenor raised its 2024 sales expectations on Thursday after its second-quarter earnings met market expectations.

The company hiked its full-year forecast for Nordic service revenues to low- to mid-single-digit organic growth, compared with the previous forecast of low single-digit growth.

Earnings before interest, tax, depreciation and amortisation (EBITDA) before other items rose to 8.79 billion Norwegian crowns ($820 million) in the April to June quarter from 8.77 billion crown a year earlier, matching analysts' expectations in a consensus poll provided by the company.

Telenor said it benefited from growth in the Nordic and Asian markets, backed by strategic investments in technology and cybersecurity.

($1 = 10.7241 Norwegian crowns)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merck's Keytruda-Padcev Combination for Bladder Cancer Approved in EU
Merck's Keytruda-Padcev Combination for Bladder Cancer Approved in EU
Sep 3, 2024
07:39 AM EDT, 09/03/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday the European Commission approved the drug combination of Keytruda and Padcev for treatment of urothelial carcinoma, the most common type of bladder cancer, in adults. The indication is for Merck's ( MRK ) proprietary treatment Keytruda combined with Padcev, jointly developed by Astellas Pharma and Seattle Genetics,...
Calliditas Therapeutics to Apply for Nasdaq Delisting as Asahi Takeover Nears Completion
Calliditas Therapeutics to Apply for Nasdaq Delisting as Asahi Takeover Nears Completion
Sep 3, 2024
07:32 AM EDT, 09/03/2024 (MT Newswires) -- Calliditas Therapeutics ( CALT ) said Tuesday that its board of directors has resolved to apply for the delisting of the company's common shares from Nasdaq Stockholm and its American depositary shares from the Nasdaq Global Select Market as Asahi Kasei is about to complete its takeover. Calliditas said Asahi Kasei announced Monday...
Top Premarket Gainers
Top Premarket Gainers
Sep 3, 2024
07:39 AM EDT, 09/03/2024 (MT Newswires) -- Sify Technologies ( SIFY ) shares surged more than 150% in recent Tuesday premarket activity, a day after the company said it had been certified to offer liquid cooling technology for Nvidia ( NVDA ) data centers as part of the DGX-Ready Data Center program. Aptose Biosciences ( APTO ) stock rose 27%...
Valeo Pharma Amended Credit Facility With Sagard
Valeo Pharma Amended Credit Facility With Sagard
Sep 3, 2024
07:37 AM EDT, 09/03/2024 (MT Newswires) -- Valeo Pharma Inc ( VPHIF ) . (VPH.TO), a Canadian pharmaceutical company, entered Tuesday into an agreement with Sagard Healthcare Royalty Partners, LP, which amends the Secured Term Loan entered into between the two companies in July 2022. According to a statement, the facility is amended to provide, among other things, an extension...
Copyright 2023-2026 - www.financetom.com All Rights Reserved